Last reviewed · How we verify
NCT05267743
Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease
Phase 4 trial testing Tegoprazan 50mg QD in Erosive Reflux Disease in 218 participants. Completed in 25 May 2022.
25 May 2022
Quick facts
| Lead sponsor | HK inno.N Corporation |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 218 |
| Start date | 16 February 2021 |
| Primary completion | 25 May 2022 |
| Estimated completion | 25 May 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Tegoprazan 50mg QD — full drug profile →
- Lansoprazole 30mg QD — full drug profile →
Conditions studied
- Erosive Reflux Disease — all drugs for Erosive Reflux Disease →
Sponsor
HK inno.N Corporation — full company profile →
Who can join
Adults 19 to 80, any sex, with Erosive Reflux Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy following oral administration once daily(QD) of 2 weeks or 4 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.
Shin CM, Choi SC, Cho JW, Kim SY, et al · · 2025 · cited 8× · PMID 39587796 · DOI 10.1111/nmo.14969
Verify or expand the search:
- PubMed search for NCT05267743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other HK inno.N Corporation trials
Trials by the same sponsor.
- NCT07277712 — A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers · Phase 1 · not yet recruiting
- NCT07192263 — Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes M · Phase 3 · not yet recruiting
- NCT06736912 — This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of · Phase 1 · not yet recruiting
- NCT06725355 — To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adul · Phase 1 · active not recruiting
- NCT06332638 — PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05267743 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HK inno.N Corporation
- Last refreshed: 29 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05267743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing